Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zebutinib first-line treatment for localized salivary gland MALT lymphoma
ChiCTR2400090558Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zanubrutinib in Extranodal marginal zone lymphoma of the salivary gland, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: complete remission rate. Started Oct 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
Extranodal marginal zone lymphoma of the salivary gland
Beyond the preview
Go deeper on ChiCTR2400090558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090558.